What to Do with the New Antibiotics?

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Multidrug-resistant Gram-negative bacteria pose a significant public health threat, risking therapeutic impasses.
• Emerging infections caused by resistant pathogens necessitate novel antimicrobial agents.

Purpose of the Study:

• To review newly introduced antibiotics for treating multidrug-resistant Gram-negative bacterial infections.
• To assess the role of these new agents in both documented and probabilistic treatment strategies.
• To highlight the importance of epidemiological data in optimizing antibiotic prescriptions.

Main Methods:

• Literature review of recent antibiotic introductions.
• Analysis of antibiotic efficacy against specific multidrug-resistant Gram-negative bacteria (Pseudomonas aeruginosa, Enterobacterales).
• Evaluation of guidelines and risk factors influencing treatment choices.

Main Results:

• Ceftolozane/tazobactam and imipenem/relebactam are key for Pseudomonas aeruginosa infections.
• Ceftazidime/avibactam and meropenem/vaborbactam target carbapenem-resistant Enterobacterales.
• Cefiderocol demonstrates broad-spectrum activity against many multidrug-resistant Gram-negative bacilli.

Conclusions:

• New antibiotics are vital additions to the therapeutic armamentarium against resistant Gram-negative infections.
• Consideration of probabilistic treatment, informed by risk factors and local ecology, is essential.
• Epidemiological data should guide the optimal use of these novel antimicrobial agents.